Onco Cell Therapy Summit Europe 2022

Onco Cell Therapy Summit Europe 2022

The Onco Cell Therapy Summit: Europe returns November 7-8 2023

Check out our sister event

“The event was very interesting and well organised. I liked the mixture of scientific talks with updates on current developments alongside more practical 'logistical and regulatory' issues one encounters in the daily life of delivering these treatments to patients in clinical trials.”

Bilyana Popova, Senior Trial Co-ordinator, UCL

HOW TO GET INVOLVED

PARTNER WITH US

It's never too early to get involved! Based on your objectives, we can create bespoke packages designed specifically for you.

From presenting your expertize on the main stage to hosting the infamous CAR-T Party. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

Discuss your objectives with Oleksiy Ihnatenko, Commercial Partnerships Manager[email protected].

OR REGISTER YOUR INTEREST IN SPONSORSHIP FOR THE WORLD ONCOLOGY CELL THERAPY CONGRESS, HERE.

REGISTER AS A DELEGATE

Innovation in cell therapy for cancer is at an all-time high, with the exploration of autologous and allogeneic therapies derived from T cells, NK cells, macrophages and beyond.

Step into interactive discussions and engaging presentations on the hottest challenges facing the cell therapy industry today. 

REGISTER YOUR INTEREST IN OUR SISTER EVENT, THE WORLD ONCOLOGY CELL THERAPY CONGRESS, HERE.

Previous Speakers

 

Dr Adil Duru

Senior Research Manager
Glycostem Therapeutics

I received my Ph.D. from the Center for Infectious Medicine (CIM), Karolinska Institutet (KI), Sweden, in 2012 where I studied MHC-class I restricted-peptide based immunomodulation of T cells and NK cells. I moved for my post-doctoral studies at the Center for Hematology and Regenerative Medicine (HERM) at KI with a focus on developing novel cell culture agents and methods as well as genetic modification strategies for ex vivo NK cell expansion.

Dr Adil Duru

Senior Research Manager
Glycostem Therapeutics

Dr Adil Duru

Senior Research Manager
Glycostem Therapeutics

I received my Ph.D. from the Center for Infectious Medicine (CIM), Karolinska Institutet (KI), Sweden, in 2012 where I studied MHC-class I restricted-peptide based immunomodulation of T cells and NK cells. I moved for my post-doctoral studies at the Center for Hematology and Regenerative Medicine (HERM) at KI with a focus on developing novel cell culture agents and methods as well as genetic modification strategies for ex vivo NK cell expansion. In parallel, I investigated the impact of novel immunomodulatory drugs and biological agents on prognosis and treatment of multiple myeloma patients.

From 2015 until 2020, I continued my research as an Assistant Professor/Group Leader at the Nova Southeastern University (NSU) Cell Therapy Institute, FL, USA, in the field of tumor immunology and immunotherapy with a specific interest in investigating NK cell interactions with different primary solid tumour models such as Melanoma and Sarcoma and developing novel TCR- and CAR-based genetically modified NK cell immunotherapies. Furthermore, I established and directed the Cell Therapy Core Facility (CTC) at NSU, which is capable of design, development, pre-clinical evaluation and optimization of cell therapy products. Additionally, I am a cofounder and shareholder of the biotech company Vycellix, which is focused on developing innovative products enhancing the immune responses against cancer.

In 2020, I joined to Glycostem Therapeutics, Netherlands, as senior research manager where I am working to develop novel robust and efficient native and engineered NK cell-based immunotherapy regimens for high-risk cancers.

 

Alicia Bertolotti

Business Support Specialist, EMEA
Bionano Genomics

Alicia Bertolotti

Business Support Specialist, EMEA
Bionano Genomics

Alicia Bertolotti

Business Support Specialist, EMEA
Bionano Genomics
 

Andrea Braun- Scherhag

VP, Global Head of Regulatory Affairs
Autolus

Andrea Braun- Scherhag

VP, Global Head of Regulatory Affairs
Autolus

Andrea Braun- Scherhag

VP, Global Head of Regulatory Affairs
Autolus
 

Ann Ager

Professor of Cellular Immunity and Immunotherapy, Division of Infection and Immunity, School of Medicine and Systems Immunity Research Institute
Cardiff University

Ann Ager

Professor of Cellular Immunity and Immunotherapy, Division of Infection and Immunity, School of Medicine and Systems Immunity Research Institute
Cardiff University

Ann Ager

Professor of Cellular Immunity and Immunotherapy, Division of Infection and Immunity, School of Medicine and Systems Immunity Research Institute
Cardiff University
 

Anna Koptina

Head of Regulatory Affairs
Mendus

Anna Koptina

Head of Regulatory Affairs
Mendus

Anna Koptina

Head of Regulatory Affairs
Mendus
 

Bakul Gupta

Co-founder & CEO
ImmTune Therapies

Dr Bakul Gupta is the CEO and Co-founder of ImmTune Therapies, a preclinical stage cell therapy biotech which is developing safe, scalable and affordable in vivo cell therapies. The company is leveraging its unique platform to effectively deliver genetic cargoes directly to targeted cells, and applying it across different indications in cell and gene therapies.

Bakul Gupta

Co-founder & CEO
ImmTune Therapies

Bakul Gupta

Co-founder & CEO
ImmTune Therapies

Dr Bakul Gupta is the CEO and Co-founder of ImmTune Therapies, a preclinical stage cell therapy biotech which is developing safe, scalable and affordable in vivo cell therapies. The company is leveraging its unique platform to effectively deliver genetic cargoes directly to targeted cells, and applying it across different indications in cell and gene therapies.

Bakul founded the company in 2019, along with her business partner, Dr George Tetley after a 6-month long research into the challenges faced by current cell and gene therapy companies. She holds a PhD and BSc in Nanotechnology and Chemistry from the UNSW Australia, and finished her postdoctoral training with Prof. Molly Stevens at Imperial College London before starting ImmTune Therapies.

She has over 10 years of experience in designing nano- and bio-materials for a diverse set of biomedical applications and has previous experience in commercialisation of medical devices. She was recently listed as the Top 30 biotech entrepreneurs to watch as part of a report produced by BioBeat.

 

Behnam Sadeghi

Head of Translational Cell Therapy Research
Karolinska Institute

Behnam Sadeghi graduated as medical doctor (MD) in 1995. Dr Sadeghi did his PhD in transplantation Immunology in 2009 at Karolinska Institute, Stockholm, Sweden. Since then, Dr Sadeghi’s research concentrated in the field of cell therapy and regenerative medicine both in clinical practice and experimental models. Dr Sadeghi established and applied decidua stromal cells (DSC) for the treatment of steroid refractory GVHD, ARDS and other acute inflammatory disorders in man.

Behnam Sadeghi

Head of Translational Cell Therapy Research
Karolinska Institute

Behnam Sadeghi

Head of Translational Cell Therapy Research
Karolinska Institute

Behnam Sadeghi graduated as medical doctor (MD) in 1995. Dr Sadeghi did his PhD in transplantation Immunology in 2009 at Karolinska Institute, Stockholm, Sweden. Since then, Dr Sadeghi’s research concentrated in the field of cell therapy and regenerative medicine both in clinical practice and experimental models. Dr Sadeghi established and applied decidua stromal cells (DSC) for the treatment of steroid refractory GVHD, ARDS and other acute inflammatory disorders in man. Other cell therapy modalities including bone marrow, adipose derived mesenchymal stromal cells (BM, Ad-MSC) are among his research interest. Currently, Dr Sadeghi is head of Translational Cell therapy Research group (TCR) at the department of CLINTEC, Karolinska Institute, Stockholm, Sweden.

 

Ben Taylor

Director, Discovery Sciences, BioPharmaceuticals R&D
AstraZeneca

Ben Taylor

Director, Discovery Sciences, BioPharmaceuticals R&D
AstraZeneca

Ben Taylor

Director, Discovery Sciences, BioPharmaceuticals R&D
AstraZeneca
 

Benjamin Rengstl

Director, Clinical Development & Director, Immunoreceptor Therapy, BioNTech Cell & Gene Therapies
BioNTech SE

Dr. Benjamin Rengstl is a trained physician and biochemist. Since 2009, he is exploring the potential of the immune system to combat cancer and infectious diseases. Between 2014 and 2016, he received his approbation as well as a PhD and a MD degree from the University of Frankfurt, Germany. During his postdoctoral training, he developed chimeric antigen receptor (CAR)-engineered T-cell therapies against lymphomas and got trained in clinical pathology. In 2017, he joined BioNTech SE located in Mainz to develop a clinical CAR-T cell candidate for treatment of solid tumors.

Benjamin Rengstl

Director, Clinical Development & Director, Immunoreceptor Therapy, BioNTech Cell & Gene Therapies
BioNTech SE

Benjamin Rengstl

Director, Clinical Development & Director, Immunoreceptor Therapy, BioNTech Cell & Gene Therapies
BioNTech SE

Dr. Benjamin Rengstl is a trained physician and biochemist. Since 2009, he is exploring the potential of the immune system to combat cancer and infectious diseases. Between 2014 and 2016, he received his approbation as well as a PhD and a MD degree from the University of Frankfurt, Germany. During his postdoctoral training, he developed chimeric antigen receptor (CAR)-engineered T-cell therapies against lymphomas and got trained in clinical pathology. In 2017, he joined BioNTech SE located in Mainz to develop a clinical CAR-T cell candidate for treatment of solid tumors. To improve CAR-T cell therapy, his team pioneered an in vivo expansion concept based on a liposomally formulated RNA vaccine for systemic delivery of CAR antigen (CAR T-cell Amplifying RNA Vaccine, CARVac). A FIH clinical trial assessing BioNTech´s novel CLDN6-specific CAR in combination with CARVac is currently ongoing. Furthermore, he is leading multiple programs to develop next generation cell- and RNA-based immunotherapies and further takes technology agnostic approaches to create new strategies for controlled modulation of the immune system.

 

 

Bernd Eschgfäller

Head of Operations, Cell & Gene Therapy Europe
Novartis

Bernd Eschgfäller

Head of Operations, Cell & Gene Therapy Europe
Novartis

Bernd Eschgfäller

Head of Operations, Cell & Gene Therapy Europe
Novartis
 

Bryan Kobel

CEO
TC Biopharm

Bryan Kobel

CEO
TC Biopharm

Bryan Kobel

CEO
TC Biopharm
 

Carole Sansoz

Director, Regulatory Affairs – CMC
ERYTECH Pharma

Carole Sansoz

Director, Regulatory Affairs – CMC
ERYTECH Pharma

Carole Sansoz

Director, Regulatory Affairs – CMC
ERYTECH Pharma
 

Chris Baldwin

Sr. Director, Cell & Gene Therapy Supply Chain
GSK

Chris Baldwin

Sr. Director, Cell & Gene Therapy Supply Chain
GSK

Chris Baldwin

Sr. Director, Cell & Gene Therapy Supply Chain
GSK
 

Dilip Patel

VP, Head of Market Access
Autolus

Dilip Patel

VP, Head of Market Access
Autolus

Dilip Patel

VP, Head of Market Access
Autolus
 

Dora Hammerl

Co-founder and R&D Manager
Pan Cancer T

Dora Hammerl

Co-founder and R&D Manager
Pan Cancer T

Dora Hammerl

Co-founder and R&D Manager
Pan Cancer T
 

Etienne Jousseaume

Head, Market Access, Cell and Gene Therapy, Europe
Novartis

Etienne Jousseaume

Head, Market Access, Cell and Gene Therapy, Europe
Novartis

Etienne Jousseaume

Head, Market Access, Cell and Gene Therapy, Europe
Novartis
 

Hélène Negre

Scientific Director Biotechnology & Bioproduction
Servier

Hélène Negre

Scientific Director Biotechnology & Bioproduction
Servier

Hélène Negre

Scientific Director Biotechnology & Bioproduction
Servier
 

Hemant Dhamne

Head, Process Development, Gene Therapy Vector Facility
Kings College London

Hemant Dhamne

Head, Process Development, Gene Therapy Vector Facility
Kings College London

Hemant Dhamne

Head, Process Development, Gene Therapy Vector Facility
Kings College London
 

Ineke Jonker-Hoogerkamp

Independent Consultant, Regulatory Affairs & Drug Development
Eagle Pharma Consult

Ineke Jonker-Hoogerkamp

Independent Consultant, Regulatory Affairs & Drug Development
Eagle Pharma Consult

Ineke Jonker-Hoogerkamp

Independent Consultant, Regulatory Affairs & Drug Development
Eagle Pharma Consult
 

Inge Jedema

Netherlands Cancer Institute/Antoni van Leeuwenhoek
Head of Translational Cellular Therapy

Inge Jedema

Netherlands Cancer Institute/Antoni van Leeuwenhoek
Head of Translational Cellular Therapy

Inge Jedema

Netherlands Cancer Institute/Antoni van Leeuwenhoek
Head of Translational Cellular Therapy
 

Inna Menkova

Co-founder & CEO
Allogenica

Inna Menkova

Co-founder & CEO
Allogenica

Inna Menkova

Co-founder & CEO
Allogenica
 

Jamal El-Mosleh

CEO
Elicera Therapeutics

Jamal El-Mosleh

CEO
Elicera Therapeutics

Jamal El-Mosleh

CEO
Elicera Therapeutics
 

Jens Pahl, PhD

Senior Scientist Translational Immunobiology
Affimed GmbH

Jens Pahl, PhD

Senior Scientist Translational Immunobiology
Affimed GmbH

Jens Pahl, PhD

Senior Scientist Translational Immunobiology
Affimed GmbH
 

Joël Plumas

Co-founder & CSO
PDC*Line Pharma

Joël Plumas

Co-founder & CSO
PDC*Line Pharma

Joël Plumas

Co-founder & CSO
PDC*Line Pharma
 

Juliana Dias Alves Pinto

Head of GMP CAR-T Production
Centre for Cell Gene & Tissue Therapeutics (CCGTT)

Juliana Dias Alves Pinto

Head of GMP CAR-T Production
Centre for Cell Gene & Tissue Therapeutics (CCGTT)

Juliana Dias Alves Pinto

Head of GMP CAR-T Production
Centre for Cell Gene & Tissue Therapeutics (CCGTT)
 

Luca Gattinoni

Director, Division of Functional Immune Cell Modulation
Leibniz Institute for Immunotherapy

Luca Gattinoni

Director, Division of Functional Immune Cell Modulation
Leibniz Institute for Immunotherapy

Luca Gattinoni

Director, Division of Functional Immune Cell Modulation
Leibniz Institute for Immunotherapy
 

Michael Hudecek

Chair of Cellular Immunotherapy, Medical Clinic and Polyclinic II
University Hospital Würzburg

Michael Hudecek

Chair of Cellular Immunotherapy, Medical Clinic and Polyclinic II
University Hospital Würzburg

Michael Hudecek

Chair of Cellular Immunotherapy, Medical Clinic and Polyclinic II
University Hospital Würzburg
 

Michael Leek

Executive Chairman
TC Biopharm

Michael Leek

Executive Chairman
TC Biopharm

Michael Leek

Executive Chairman
TC Biopharm
 

Mikhail Steklov

Team Lead, Cell Fitness Group
T-Knife Therapeutics

Mikhail Steklov

Team Lead, Cell Fitness Group
T-Knife Therapeutics

Mikhail Steklov

Team Lead, Cell Fitness Group
T-Knife Therapeutics
 

Michael Traxlmayr

Senior Scientist
BOKU

Michael Traxlmayr

Senior Scientist
BOKU

Michael Traxlmayr

Senior Scientist
BOKU
 

Olivier Negre

CSO
Smart Immune

Olivier Negre

CSO
Smart Immune

Olivier Negre

CSO
Smart Immune
 

Paul Ibbett

Scientist II
MiNK Therapeutics

Paul Ibbett

Scientist II
MiNK Therapeutics

Paul Ibbett

Scientist II
MiNK Therapeutics
 

Praveen Malhotra

VP, Head of Information Technology
TCR2 Therapeutics

Praveen Malhotra

VP, Head of Information Technology
TCR2 Therapeutics

Praveen Malhotra

VP, Head of Information Technology
TCR2 Therapeutics
 

Rebecca Street-Howard

Cell and Gene Therapy Systems Director
GSK

Rebecca Street-Howard

Cell and Gene Therapy Systems Director
GSK

Rebecca Street-Howard

Cell and Gene Therapy Systems Director
GSK
 

Robert Igarashi

Head of Discovery & Pre-Clinical Development
Kiadis Pharma, a Sanofi Company

Robert Igarashi

Head of Discovery & Pre-Clinical Development
Kiadis Pharma, a Sanofi Company

Robert Igarashi

Head of Discovery & Pre-Clinical Development
Kiadis Pharma, a Sanofi Company
 

Rogier Rooswinkel

General Partner
Forbion

Rogier Rooswinkel

General Partner
Forbion

Rogier Rooswinkel

General Partner
Forbion
 

Sarah Tettamanti

Postdoctoral Research Scientist
M. Tettamanti Foundation Research Center

Sarah Tettamanti

Postdoctoral Research Scientist
M. Tettamanti Foundation Research Center

Sarah Tettamanti

Postdoctoral Research Scientist
M. Tettamanti Foundation Research Center
 

Sebastian Torres

Sr. Director, Process Development & Manufacturing
SQZ Biotechnologies

Sebastian Torres

Sr. Director, Process Development & Manufacturing
SQZ Biotechnologies

Sebastian Torres

Sr. Director, Process Development & Manufacturing
SQZ Biotechnologies
 

Stuart Curbishley

Head of Business and Project Development – Advanced Therapies
University of Birmingham

Stuart Curbishley

Head of Business and Project Development – Advanced Therapies
University of Birmingham

Stuart Curbishley

Head of Business and Project Development – Advanced Therapies
University of Birmingham
 

Sven Kili

CEO
Antion Biosciences

Sven Kili

CEO
Antion Biosciences

Sven Kili

CEO
Antion Biosciences
 

Sicco Popma

CSO
Accelerated Biosciences

Sicco Popma

CSO
Accelerated Biosciences

Sicco Popma

CSO
Accelerated Biosciences
 

Troels Jordansen

CEO
Glycostem Therapeutics

Troels Jordansen

CEO
Glycostem Therapeutics

Troels Jordansen

CEO
Glycostem Therapeutics
 

Tomasz Rygiel

Co-founder & Member of the Board
Cellis

Tomasz Rygiel

Co-founder & Member of the Board
Cellis

Tomasz Rygiel

Co-founder & Member of the Board
Cellis

Previous Attendees

45%
Biotech
20%
Pharmaceutical
15%
Researchers
20%
Service Providers & Consultants

Biotech

Pharmaceutical

Researchers

Service Providers & Consultants

OUR CELL THERAPY COMMUNITY

Register your interest

The agenda for the World Oncology Cell Therapy Congress Europe will be released soon.

Fill out this form to register your interest and be the first to recieve the agenda when it becomes available!

REGISTER YOUR INTEREST

Why Attend

Europe is a powerhouse of research but has been struggling to keep pace with development in the US. Get multiple perspectives during panel discussions on how to attract investment from C-suite executives and investors and explore European regulatory and reimbursement challenges for the cell therapy field. At the Onco Cell Therapy Summit: Europe 2022, we:

  • Brought together over 200 of Europe’s leading innovators and investors to drive partnerships, collaborations and drive adoptive cell therapies to the market

  • Addressed durability, reduce exhaustion, and build in optimal approaches for targeting antigen heterogeneity to hit the tumour microenvironment

  • Explored genome-editing, iPSC-derived approaches and management strategies for chromosomal abnormalities and translocations for allogeneic cell therapy development

  • Established robust, scalable and flexible vein-to-vein processes to enhance just in time delivery of cell therapies

TESTIMONIALS

Resources

Download Resource

2023 PARTNERS

Exhibitors

PARTNER WITH US

Based on your objectives, we can create bespoke packages designed specifically for you – from presenting your expertise on the main stage, to hosting a private dinner. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

To discuss your objectives and partnership opportunities please contact Oleksiy Ihnatenko, Commercial Partnerships Manager, [email protected]

REGISTER YOUR INTEREST

Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact Laura Hobson, Senior Marketing Manager, [email protected]

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Preparing registration...

TERMS & CONDITIONS

In the event that Kisaco Research postpones an event for any reason or changes the event format to ‘virtual event’, any in-person registrations for this event will be automatically transferred to the virtual registration package. The delegate will receive a credit note for the difference in ticket value from the fee paid. You may use this credit for another Kisaco Research event to be mutually agreed with Kisaco Research, which must occur within 12 months from the date of the event which the delegate had originally registered for.

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us